Ongoing Trials with Early PET Response–Adapted Therapies
| Study title/description | Study group (reference) | Form of lymphoma | Main PET-driven intervention | Study type |
|---|---|---|---|---|
| 18F-FDG PET–stratified R-DICEP and R-BEAM/ASCT for diffuse large B-cell lymphoma (PET CHOP) | Alberta Cancer Board (30) | DLBCL | Salvage with HD + ASCT if PET results are positive after 2× R-CHOP | Phase II |
| Associations of rituximab and chemotherapy with PET-driven strategy for lymphoma (LNH2007-3B) | GELA (31) | DLBCL | Salvage with HD + ASCT if PET results are positive after 2× R-CHOP | Phase III* |
| Tailoring treatment for B-cell NHL on basis of PET results midtreatment | British Columbia Cancer Agency (32) | Advanced DLBCL | 4 cycles of R-ICE if PET results are positive after 4× R-CHOP | Phase II |
| 18F-FDG PET for predicting relapse in NHL patients undergoing chemotherapy with or without ASCT | Johns Hopkins University (33) | Aggressive NHL | Salvage with HD + ASCT if PET results are positive after 2× or 3× CHOP or R-CHOP | Phase II |
| PET-guided therapy of aggressive NHL | University Hospital, Essen, Germany (34) | Aggressive NHL | CHOP or R-CHOP vs. Burkitt lymphoma regimen if PET results are positive after 2× CHOP or R-CHOP | Phase III |
| RAPID trial | U.K. NCRI Lymphoma Group (91) | Early–stage HL | Randomization to RT vs. no RT if PET results are negative after 3× ABVD | Phase III |
| HD16 protocol for early-stage HL | German Hodgkin Study Group (35) | Early-stage HL | No radiotherapy in experimental arm if PET results are negative after 2× ABVD | Phase III |
| 18F-FDG PET–guided therapy or standard therapy for stage I or II HL (H10 protocol) | EORTC–GELA–IIL (36) | Early-stage HL | No radiotherapy in experimental arm if PET results are negative after 2× ABVD | Phase III |
| PET-adapted chemotherapy for advanced HL | GITIL (39) | Advanced HL | Intensification to BEACOPPesc if PET results are positive after 2× ABVD | Phase II |
| 18F-FDG PET response–adapted therapy for advanced-stage HL (RATHL) | U.K. NCRI Lymphoma Group (40) | Advanced HL | Intensification to BEACOP if PET results are positive after 2× ABVD | Phase III* |
| HD + ASCT in patients with positive results of PET after 2× ABVD and RT vs. no RT in patients with negative results of PET (HD0801) | IIL (41) | Advanced HL | Salvage regimen if PET results are positive after 2× ABVD | Phase III* |
| HD18 protocol for advanced-stage HL | German Hodgkin Study Group (42) | Advanced HL | 4× vs. 8× BEACOPPesc in experimental arm if PET results are negative after 2 cycles | Phase III |
↵* No randomization regarding PET response–adapted therapy.
R-DICEP = rituximab + dose-intensive cyclophosphamide, etoposide, and cisplatin; R-BEAM = rituximab, carmustine, etoposide, cytarabine, and melphalan; CHOP = cyclophosphamide–doxorubicin–vincristine–prednisone; DLBCL = diffuse large B-cell lymphoma; HD = high-dose chemotherapy; R-CHOP = rituximab–cyclophosphamide–doxorubicin–vincristine–prednisone; GELA = Groupe d'Etudes des Lymphomes de l'Adulte; R-ICE = rituximab–ifosfamide–carboplatin–etoposide; RT = radiotherapy; EORTC = European Organization for Research and Treatment of Cancer; IIL = Intergruppo Italiano dei Linfomi; GITIL = Gruppo Italiano Terapie Innovative nei Linfomi; RATHL = response-adapted therapy in Hodgkin lymphoma.